{"url_path":"/sec/bbot/8-k/2026-06-22/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1869105/0001193125-26-277513-index.html","accession_number":"0001193125-26-277513","cik":"0001869105","ticker":"BBOT","issuer_name":"BridgeBio Oncology Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1869105/0001193125-26-277513-index.html","primary_entity_key":"0001869105","primary_entity_name":"BridgeBio Oncology Therapeutics, Inc."},"word_count":102,"has_tables":true,"body_markdown":"Item 5.02.\n\nDeparture of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nOn June 16, 2026, Michelle Doig notified BridgeBio Oncology Therapeutics, Inc. (the “Company”), of her resignation as a member of the Board of Directors of the Company (the “Board”) upon the completion of her term as a Class I director, effective as of June 16, 2026, the date of the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Ms. Doig’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices."}